Therefore, there is a possibility that the neutralizing anti-HMGB1 monoclonal antibody and glycyrrhizin may bind to the extracellular HMGB1 accumulated on the Aβ plaques in the AD brain, cancel the inhibitory effects of HMGB1 on microglial Aβ phagocytosis, and then may provide novel therapeutic options for the AD treatment. The gene discussed is HMGB1; the disease is Alzheimer disease.